
Versameb Strengthens its Board of Directors
Significant appointments of experienced drug development and financial experts – Hernán Levett, Dr Lily Geidelberg, Paul Korner, MD, MBA and Dr Alexandre LeBeaut...
Significant appointments of experienced drug development and financial experts – Hernán Levett, Dr Lily Geidelberg, Paul Korner, MD, MBA and Dr Alexandre LeBeaut...
The Investigator Initiated Phase II Trial at MD Anderson Cancer Center combining CB-103 and Venetoclax for the treatment of rr/r-T-ALL patients is now open for recruitment...
31.01.2023
BioVersys AG announces first patient dosed in Phase 2a clinical trial with BVL-GSK099, to investigate a new treatment concept to address multidrug-resistance tuberculosis...
05.01.2023
BioVersys AG announces extension of its Series C investment round to CHF 32.6 million as the AMR Action Fund makes its first European-based investment...
26.10.2022
We are pleased to announce that Christian Harr (current COO) will become the new CEO of Tech Park Basel. He will take up the new position on...